WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (HKG: 2359, SHA: 603259), has signed an expanded Memorandum of Understanding (MOU) with South Korea’s LigaChem Biosciences, Inc. to accelerate the development of next-generation antibody drug conjugates (ADCs).
Partnership Details
Under the expanded agreement, WuXi XDC will leverage its fully integrated ADC discovery service platform to enhance the speed and efficiency of LigaChem’s ADC development programs. LigaChem will utilize WuXi XDC’s cutting-edge technologies and expertise to advance its ADC candidates from discovery to development, streamlining the process. Additionally, LigaChem will use WuXi XDC’s integrated ADC development and manufacturing platform to support multiple ADC projects. Financial terms were not disclosed.-Fineline Info & Tech
Leave a Reply